ERIS - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 05 Nov 25, 7:43 am

Technical Rating: 3.4

📉 ERIS Lifesciences is currently in a mild downtrend with weakening momentum. Entry near 1,550–1,570 ₹ may offer a better risk-reward setup, while resistance near 1,640–1,680 ₹ could cap upside in the short term.

📈 Technical Analysis

• 📉 Chart Pattern: The stock is showing signs of a pullback from its recent highs, forming lower highs and lower lows — a mild downtrend.
• 📊 Moving Averages: Price is below the 50-DMA (1,639 ₹) but slightly above the 200-DMA (1,553 ₹), indicating short-term weakness but long-term support.
• 📉 RSI (42.2): Below neutral, suggesting bearish momentum and lack of buying strength.
• 📉 MACD (-9.51): Deep in negative territory, confirming bearish crossover and downward momentum.
• 📉 Bollinger Bands: Price near lower band, indicating oversold conditions but no clear reversal signal yet.
• 📉 Volume Trend: Current volume (41,165) is significantly below 1-week average (1,46,696), showing weak participation and low conviction.

📍 Entry & Exit Zones

• ✅ Entry Zone: 1,550 ₹ – 1,570 ₹ (near 200-DMA and recent support)
• 🚪 Exit Zone: 1,640 ₹ – 1,680 ₹ (resistance from 50-DMA and previous swing highs)

📊 Trend Status

• 📉 Current Trend: Reversing from uptrend to mild downtrend
• ⚠️ Bias: Bearish unless RSI crosses 50 and MACD flattens

✅ Positive

• Quarterly PAT surged from 30.5 Cr. to 100 Cr., a 487% jump — strong earnings rebound.
• Price still above 200-DMA, indicating long-term support remains intact.
• Industry PE (33.1) is much lower than stock PE (136), suggesting strong investor expectations.

⚠️ Limitation

• High P/E (136) and negative PEG (-3.14) indicate overvaluation and poor growth alignment.
• Weak ROCE (6.86%) and ROE (3.02%) reflect inefficient capital use.
• MACD and RSI both signal bearish momentum; volume is also declining.

📉 Company Negative News

• FII holding dropped by 1.18%, indicating reduced foreign investor confidence.

📈 Company Positive News

• Massive quarterly profit growth (487%) may boost sentiment if sustained in future quarters.

🏭 Industry

• Pharmaceutical sector remains stable with moderate growth outlook.
• ERIS trades at a significant premium to industry PE, reflecting high growth expectations.

🧾 Conclusion

• ERIS Lifesciences is reversing from a prior uptrend and currently shows bearish technical signals.
• Short-term traders should wait for confirmation of support near 1,550 ₹ before entering.
• Long-term investors should monitor valuation and earnings consistency before adding exposure.

Sources: Eris Lifesciences chart & indicators, Technical overview & momentum, Strength & direction analysis

Daily Stock Tips

+2

.